
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings Inc is poised for growth in the U.S. healthcare sector, particularly with the increased market share projections for its POSLUMA PSMA PET imaging product, expected to rise from a low to high single-digit share by early 2025. The company is also set to benefit from a new Pylarify formulary that will enhance production capabilities, potentially revitalizing growth in the fourth quarter of 2026 and beyond. Additionally, there is optimism surrounding the company’s overall earnings per share (EPS) growth in 2026-2027, driven by non-Pylarify segments exceeding current growth and margin expectations amidst a relatively low price-to-earnings (P/E) ratio of under 10x.
Bears say
Lantheus Holdings Inc. is experiencing a concerning downward trend in its financial performance, as evidenced by a significant decline in Pylarify revenue, which reported $260 million—an 8% year-over-year drop and approximately $14 million below expectations. The company is also facing challenges with unit growth, which has been lower than anticipated at only 2% year-over-year and 4% quarter-over-quarter, compounded by a notable 10% price headwind during the quarter. Furthermore, compared to its profitable SMID MedTech peers, Lantheus's growth profile for 2025-2026 is projected to be inferior, prompting a negative outlook on the stock.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares